Dario Sterker
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Journal: Nature cancer
Published: June 17, 2024
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Journal: Nature cancer
Published: May 22, 2023
A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues.
Journal: Frontiers in pharmacology
Published: September 29, 2021
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
Journal: Journal of medicinal chemistry
Published: September 15, 2020
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Journal: Molecular cancer therapeutics
Published: December 16, 2018
Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.
Journal: Cancer chemotherapy and pharmacology
Published: May 16, 2017
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Journal: Cancer cell
Published: November 03, 2014
JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 02, 2013
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Journal: Molecular cancer therapeutics
Published: June 02, 2012
Last Updated: 09/26/2026